Neurologic involvement in patients with atypical Chediak-Higashi disease

Wendy J. Introne, MD
Wendy Westbroek, PhD
Catherine A. Groden,
MS, CRNP

Vikas Bhambhani, MD
Gretchen A. Golas, MS,
CRNP

Eva H. Baker, MD, PhD
Tanya J. Lehty, MD
Joseph Snow, PhD
Shira G. Ziegler, BA
May Christine V.

Malicdan, MD, PhD
David R. Adams, MD,
PhD

Heidi M. Dorward, MS
Richard A. Hess, PhD
Marjan Huizing, PhD
William A. Gahl, MD,
PhD

Camilo Toro, MD

Correspondence to
Dr. Introne:
wintrone@mail.nih.gov

Supplemental data
at Neurology.org

ABSTRACT

Objective: To delineate the developmental and progressive neurodegenerative features in 9 young adults with the atypical form of Chediak-Higashi disease (CHD) enrolled in a natural history study.

Methods: Patients with atypical clinical features, but diagnostically confirmed CHD by standard evaluation of blood smears and molecular genotyping, underwent complete neurologic evaluation, MRI of the brain, electrophysiologic examination, and neuropsychological testing. Fibroblasts were collected to investigate the cellular phenotype and correlation with the clinical presentation.

Results: In 9 mildly affected patients with CHD, we documented learning and behavioral difficulties along with developmental structural abnormalities of the cerebellum and posterior fossa, which are apparent early in childhood. A range of progressive neurologic problems emerge in early adulthood, including cerebellar deficits, polyneuropathies, spasticity, cognitive decline, and parkinsonism.

Conclusions: Patients with undiagnosed atypical CHD manifesting some of these wide-ranging yet nonspecific neurologic complaints may reside in general and specialty neurology clinics. The absence of the typical bleeding or infectious diathesis in mildly affected patients with CHD renders them difficult to diagnose. Identification of these individuals is important not only for close surveillance of potential CHD-related systemic complications but also for a full understanding of the natural history of CHD and the potential role of the disease-causing protein, *LYST*, to the pathophysiology of other neurodevelopmental and neurodegenerative disorders. *Neurology*® 2017;88:e57–e65

GLOSSARY

BMT = bone marrow transplantation; **CHD** = Chediak-Higashi disease; **FSIQ** = full-scale IQ; **HLH** = hemophagocytic lymphohistiocytosis; **LRO** = lysosome-related organelle; **LYST** = lysosomal trafficking regulator; **PD** = Parkinson disease; **qPCR** = quantitative PCR; **RBD** = REM sleep behavior disorder.

Chediak-Higashi disease (CHD; OMIM #214500) is a rare, autosomal recessive disorder with hematologic, pigmentary, and neurologic manifestations caused by biallelic pathogenic variants in the lysosomal trafficking regulator gene *LYST*.¹ Typical patients with CHD present with immunodeficiency and hemophagocytic lymphohistiocytosis (HLH), or the accelerated phase,^{2,3} along with variable degrees of bleeding, due to a delta storage pool deficiency of platelets, and oculocutaneous albinism.⁴ Without therapy, children with classic CHD die of infections or from complications of HLH in the first decade. Bone marrow transplantation (BMT) prevents both of these outcomes, but does not stop the progression of neurologic deficits.⁵ The neurologic involvement is characterized by subtle and nonspecific early neurodevelopmental issues including learning and behavioral deficits in childhood followed in early adulthood by a progressive neurodegeneration with varying degrees of cerebellar dysfunction, peripheral neuropathy, spasticity, dystonia, parkinsonism, impaired cognition, and premature death.⁶

This article is republished with corrections from the original version (*Neurology* 2016;86:1320–1328). An Expression of Concern (2017;88:721), a Correction, (2017;88:720) and a Partial Retraction (2017;88:721) have been published.

From the Office of the Clinical Director (W.J.I., C.A.G., V.B., G.A.G., W.A.G., C.T.) and Human Biochemical Genetics Section, Medical Genetics Branch (W.W., S.G.Z., M.C.V.M., D.R.A., H.M.D., R.A.H., M.H., W.A.G.), National Human Genome Research Institute, Department of Radiology and Imaging Sciences, Clinical Center (E.H.B.), Electromyography Section, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke (T.J.L.), and Office of the Clinical Director, National Institute of Mental Health (J.S.), National Institutes of Health, Bethesda, MD; and Metabolic and Clinical Geneticist (V.B.), Department of Medical Genetics, Children's Hospitals and Clinics of Minnesota, Minneapolis.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Adults with mild forms of CHD, despite harboring biallelic *LYST* variants, may escape early detection and consideration for BMT, because early life-threatening infections, bleeding, and HLH complications are muted.^{7,8} Nevertheless, such patients develop striking neurologic declines that may not be recognized as part of the CHD phenotype. Here, we review the natural history and the spectrum of neurologic involvement in 9 mildly affected adult patients with CHD, including their history, clinical, brain MRI, electrophysiologic, molecular, and cell biological findings.

METHODS **Standard protocol approvals, registrations, and patient consents.** Patients with a presumed diagnosis of CHD were referred to and enrolled in clinical protocol 00-HG-0153, Investigations into Chediak-Higashi Syndrome and Related Disorders (clinicaltrials.gov identifier NCT00005917) approved by the National Human Genome Research Institute Institutional Review Board. Written informed consent was obtained. All evaluations took place at the NIH Clinical Center between 2005 and 2014. Under a separate consent, skin biopsies were performed to obtain fibroblasts.

Laboratory investigations. Specialized laboratory investigations included monitoring for HLH, peripheral blood smears to confirm the presence of giant inclusions within neutrophils, microscopic hair examination, and whole mount electron microscopy of platelets to quantify dense bodies.

Neurophysiology. Nerve conduction studies were performed mainly on the median and sural sensory nerves and the peroneal and median motor nerves. Measurements used standard methodology with a Nicolet Viking Select machine (Cardinal Health, Dublin, OH) and were compared to department-based normative values.⁹ Needle EMG was performed using a concentric needle and filter settings of 2K–10K with spontaneous and motor unit activity recorded according to standard methodology.

MRI. The standard MRI examination of the brain consisted of sagittal T1-weighted, axial T2-weighted, axial T1-weighted, axial diffusion tensor, postcontrast axial T1-weighted, postcontrast axial fluid-attenuated inversion recovery, and postcontrast sagittal 3D T1-weighted images; 2 patients had similar examinations without administration of contrast material, and one patient was not scanned due to intense claustrophobia. The field strength was either 1.5T or 3T. We used elements of previously published metrics of posterior fossa traits to evaluate the sagittal configuration of the posterior fossa.¹⁰ A superior cerebellar vermis angle was measured as the intersection of 2 line segments, one segment originating at the opening of the aqueduct into the fourth ventricle to the vein of Galen and the other projecting from the vein of Galen through the straight sinus into the torcula herophili. This angle was measured after reformatting the 3D T1-weighted images into an exact midsagittal plane, as defined by the plane of the falx cerebri. Measurements in patients were compared against sex-matched normal controls (in a 2:1 ratio)

enrolled in other research protocols who had undergone similar imaging studies that included axial or sagittal 3D T1-weighted images.

Cells. Primary dermal fibroblasts were cultured from a forearm skin biopsy, as described.^{8,11} Cell culture conditions are described in the e-Methods at Neurology.org.

Light microscopy. Bright field images of hair were obtained using a Zeiss (Oberkochen, Germany) Axiovert 200M with a Plan NeoFluar 40×/1.3 oil differential interference contrast objective. Images were obtained with an AxioCam HRC color camera with Axiovision software version 4.5.0 (Carl Zeiss, Micro-imaging Inc., Jena, Germany).

Molecular analysis, quantitative real-time PCR (qPCR), high-molecular-weight immunoblotting, and confocal laser-scanning microscopy. See the e-Methods for a description of molecular analysis, qPCR, high-molecular-weight immunoblotting, and confocal laser-scanning microscopy.

RESULTS **Patient cohort.** Nine patients (8 male, 1 female; age 16–35 years) were diagnosed with CHD by identifying giant inclusions within leukocytes on standard peripheral blood smears; the diagnoses were confirmed by biallelic genetic *LYST* variants (table 1). No patient had experienced life-threatening infections or symptoms of the accelerated phase; none had undergone BMT. Hair (showing characteristic pigment granulation), skin (showing hypopigmentation), and blood smear (showing giant granules in leukocytes) findings were all consistent with CHD (figure 1). Other clinical characteristics are summarized in table 1. Patient CHD-20 lived for over 3 decades without a BMT and without HLH symptoms or signs. Despite these clinical indications of mild disease, this patient had classic CHD by molecular analysis (*LYST* gene and *LYST* protein analysis); he died of HLH at age 34 years.

Molecular and cellular studies. Biallelic variants in *LYST* were identified in every patient (figure e-1A) except CHD-5, who was heterozygous for a novel missense variant; a second variant could not be detected. However, gDNA (derived from fibroblasts) sequencing showed 2 variant peaks of equal intensity (figure e-1B, arrow), indicating the presence of equal allelic amounts of DNA. In contrast, cDNA (derived from fibroblast mRNA) sequencing showed a higher intensity band for the variant missense allele (T) compared to the normal allele (G) (figure e-1B), indicating that the normal allele may carry a cryptic variant (deep intronic, or 3' or 5' UTR) causing mRNA decay. In fact, qPCR showed a significant reduction (63%–69%) of *LYST* mRNA using 3 different probes ($p < 0.0001$) (figure e-1B).

The pathogenicity of the 6 missense variants in our patients was examined using a 5' nuclease allelic

Table 1 Clinical and molecular characteristics of atypical Chediak-Higashi disease

Patient	Age at initial NIH evaluation, y	Age at diagnosis, y	LYST variants	Pigmentary findings	Infectious history	Bleeding history	HLH
CHD-5	20	19	p.V2651F, ? second mutation	Ocular albinism, decreased visual acuity	Cutaneous MRSA at age 19 y	Gingival bleeding	No
CHD-6	35	35	p.E805NfsX1, p.N3376S	Ocular albinism	None	Recurrent nosebleeds requiring electrocautery	No
CHD-17	28	0.7	p.L1425YfsX1, p.E2810K	No ocular albinism, gray hue to hair	Recurrent infections in childhood, decreased with age	Gingival bleeding	No
CHD-18 ^a	22	22	p.R1104X, p.G3408R	Ocular albinism, gray hue to hair	None	Gingival bleeding, easy bruising	No
CHD-19 ^a	16	16	p.R1104X, p.G3408R	Ocular albinism, decreased visual acuity, gray hue to hair	None	Gingival bleeding, nosebleeds, easy bruising	No
CHD-20	31	0.3	p.R1104X, p.R1104X	Ocular albinism, silver-gray hair	Severe infections from age 3 mo (9 hospitalizations by age 1 y)	Gingival bleeding, easy bruising	Age 34
CHD-23 ^b	26	0.6	p.A1454D, p.Y1687X	Ocular albinism, silvery hair, fair skin	Recurrent infections until diagnosis, improved with IVIg, recurrent skin infections as adult	Gingival bleeding, nosebleeds	No
CHD-24 ^b	23	0.1	p.A1454D, p.Y1687X	Ocular albinism	Received IVIg from age 2 mo to adolescence, recurrent skin infections as adult	Recurrent nosebleeds requiring electrocautery	No
CHD-26	21	Newborn	p.R503X, p.G3309S	Ocular albinism, silvery hair, mottled skin pigment	Bilateral osteomyelitis, recurrent skin infections as adult	Gingival bleeding, recurrent nosebleeds	No

Abbreviations: HLH = hemophagocytic lymphohistiocytosis; IVIg = IV immunoglobulin; MRSA = methicillin-resistant *Staphylococcus aureus*.

Variant nomenclature based on NM_000081 and NP_000072.

^{a,b} Two pairs of siblings.

discrimination (TaqMan) assay. None of these *LYST* variants was present in a DNA panel of 100 healthy individuals, indicating they are not common polymorphisms. Querying the ExAC databases of whole exome data revealed that most of the *LYST* variants were not present, and a few variants had very small allele frequencies ($p < 0.0001$), where none were homozygotes. In addition, the deleteriousness of the missense variants was assessed using 3 analysis programs, SIFT, PolyPhen-2, and Align-GVGD. All variants except p.E2810K were deemed damaging by all 3 programs. SIFT predicted p.E2810K to be tolerated, while PolyPhen-2 considered it possibly damaging and Align-GVGD predicted it to be deleterious.

The molecular alterations in our patients with mild CHD translated into reduced *LYST* protein expression in their cultured fibroblasts. We used CHD-4 (early-onset CHD, harboring deleterious variants p.R514X and p.F3298SfsX6)¹² as a negative control, lacking *LYST* protein expression (figure 2A, lane 6). CHD-5 (figure 2A, lane 5) and CHD-16 (figure 2A, lane 3) showed no *LYST* expression. The mildly affected CHD-18, CHD-17, and CHD-6 (figure 2A, lanes 1, 2, and 4) showed reduced *LYST* expression compared to control.

Cultured fibroblasts from patients with CHD. The cellular phenotype of the patients with CHD reflected the severity of their molecular defects. In general, CHD

cells have enlarged lysosomes and lysosome-related organelles (LROs) in various cell types such as fibroblasts, melanocytes, and polymorphonuclear leukocytes.^{8,13} We previously established that the size of lysosomes and LROs correlated with the severity of the disease,⁸ and we found this to be true for the lysosomes in fibroblasts of our atypical CHD cases (figure 2B). We included previously described CHD-4 (classic CHD) and CHD-6 (mild late-onset CHD) for comparison.⁸ CHD-4 fibroblasts exhibited giant lysosomes clustered around the nucleus while CHD-6 fibroblasts had a mixture of normal and slightly enlarged lysosomes in the perinuclear and peripheral areas. CHD-5 fibroblasts exhibited a cellular phenotype between that of CHD-4 and CHD-6 cells, with enlarged lysosomes in the perinuclear area and normal-sized lysosomes in the periphery. CHD-17 and CHD-18 closely resembled the cellular phenotype of control fibroblasts, with normal-sized lysosomes distributed in the perinuclear and peripheral regions.

Clinical neurology. All 9 patients exhibited developmental impairment manifested by learning disabilities (table 2). Full-scale IQ (FSIQ) at baseline NIH visit evaluated using either the Wechsler Abbreviated Scale of Intelligence¹⁴ or Wechsler Adult Intelligence Scale, 3rd edition,¹⁵ varied from 64 to 95, with an average baseline FSIQ of 80. Six patients had cerebellar

Figure 1 Hair and skin pigmentation, blood smears, and hair microscopy of representative patients with atypical Chediak-Higashi disease (CHD)

(A) Hair and skin pigmentation. (B) Characteristic giant inclusions (arrows) within neutrophils are numerous and variable in size. (C) A solitary giant inclusion is typically seen within lymphocytes. (D) Light microscopy reveals atypical pigment clumping within hair shafts. Note uniform distribution of pigment in normal hair (CHD-5 inset).

signs, largely limb dysmetria, and 4 had parkinsonism; 3 were L-dopa responsive, and 2 displayed “on-off” fluctuations and peak-dose dyskinesia. Three patients had a mild postural tremor, 7 displayed weakness, and 4 had subtle sensory deficits manifesting as loss of distal vibratory sensation. Plantar responses were extensor in 4 patients, and all had absent or decreased deep tendon reflexes in the lower extremities, reflecting concurrent central and peripheral nervous system involvement. Two patients, both with parkinsonism, experienced active vivid dreaming clinically suggestive of REM sleep behavior disorder (RBD).

Brain imaging. MRI examinations revealed 1 patient with mild cerebral atrophy, 1 with mild cerebellar atrophy, 2 with mild cerebral and cerebellar atrophy, and 1 with moderate cerebral and cerebellar atrophy (figure 3, E, F, and I). In general, atrophy correlated with longer disease duration, more severe cognitive disabilities, or motor dysfunction. There were no supratentorial focal lesions, heterotopia, structural defects, or white matter signal abnormalities.

However, a group-specific morphologic variation in the configuration of the posterior fossa was observed in midsagittal images. The angle enclosing

the superior cerebellar vermis was more acute in patients with CHD (mean 64°, range 52°–79°) (figure 3, A–F) than in age- and sex-matched controls (mean 86°, range 72°–97°), with $p = 0.00002$ by 2-tailed heteroscedastic t test.

Electrophysiology. Seven patients underwent studies of nerve conduction and needle EMG; 5 had follow-up studies within 1–2 years. Table e-1 gives the initial study values, as well as 1- and 2-year follow-up values when available. At baseline, 2 patients had no detectable sural responses and 3 patients had low responses. Median nerve sensory response was low in one patient. For the motor nerves, one patient had a low peroneal response. All patients had normal median motor responses. The conduction velocities were all normal except for the median sensory and peroneal motor response in CHD-20, likely related to axonal loss and not in the demyelinating range.

Needle EMG was performed in proximal and distal leg muscles in 6 patients. Three patients had acute or chronic neurogenic changes in the distal leg muscles, although one individual had no evidence of a neuropathy by nerve conduction studies. Two

Figure 2 LYST protein expression and lysosome size and distribution in Chediak-Higashi disease (CHD) fibroblasts

(A) High-molecular-weight immunoblots of protein extracts from normal control fibroblasts (lane 7), classic LYST-negative control fibroblasts CHD-16 (lane 3) and CHD-4 (lane 6), and 4 different CHD patients' fibroblast cultures; α -tubulin was used as a loading control. Fibroblasts from patients with atypical CHD (CHD-18, lane 1; CHD-17, lane 2; CHD-6, lane 4; and CHD-5, lane 5) have reduced levels of LYST expression. CHD-5 cells showed no LYST protein, despite the presence of a low level of residual RNA (~20% of control). Please refer to our previous publication [Manoli I, Golas G, Westbroek W, et al. Chediak-Higashi syndrome with early developmental delay resulting from paternal heterodisomy of chromosome 1. *Am J Med Genet A* 2010;152A:1474-1483] for methods and antibody information. (B) Fibroblasts are stained with LAMP-1 antibodies (green) to visualize lysosomal membranes and with an F-actin marker (phalloidin, red) to visualize the cell boundaries. Control fibroblasts show a typical distribution of lysosomes throughout the cell. Classic CHD-4 fibroblasts show enlarged lysosomes restricted to the perinuclear area. CHD-5 fibroblasts show enlarged lysosomes in the perinuclear area and normal-sized lysosomes in the periphery. CHD-6 fibroblasts show slightly enlarged lysosomes. CHD-17 and CHD-18 fibroblasts have slightly enlarged lysosomes with a typical distribution of lysosomes throughout the cell. Marked white dotted squares in left panels are zoomed out in right panels. Scale bar 20 μ m.

patients had electrodiagnostic evidence of an axonal sensorimotor polyneuropathy. Three individuals had an axonal sensory polyneuropathy.

On longitudinal follow-up, after 2 years, 2 individuals had developed an axonal neuropathy by nerve conduction studies. One patient also had a very low median motor response, but a limited electrodiagnostic study could not further define the cause. Only 2 patients had repeat EMG studies of 2 leg muscles; both showed progressive neurogenic changes that could be associated with additional motor neuron pathology.

DISCUSSION Among the ~500 cases of CHD reported,¹⁶ genotype and phenotype correlate well.^{7,8,17} In general, patients with classic CHD have 2 severe/pathogenic *LYST* variants, while mildly affected individuals have one severe and one milder variant (e.g., missense). While *LYST* protein expression in

cultured fibroblasts reflects the severity of the non-neurologic aspects of the disease (figure 2A),¹¹ the neurologic complications of CHD affect all patients without regard to the severity of their *LYST* variants.

LYST contains 3,801 amino acids, has a molecular weight of 430 kDa, and possesses ARM/HEAT repeat motifs that mediate membrane interactions and WD-40 repeats that function in protein interactions.¹⁸ Adjacent to the WD-40 repeats is the amino acid sequence WIDL, together characterizing the Beige and Chediak (BEACH) group of proteins.^{16,18} *LYST* is widely expressed, including brain and bone marrow. *LYST* functions in trafficking lysosomes and regulating lysosomal morphology¹⁶; the absence of *LYST* results in reduced lysosome fission without altering fusion, and overexpression of *LYST* results in a faster rate of lysosome fission.¹⁹ CHD fibroblasts have giant vesicles that stain with LRO markers,

Table 2 Neurologic characteristics of atypical Chediak-Higashi disease

Patient	Neurodevelopmental history	FSIQ	Cerebellar dysfunction	Parkinsonism and dystonia	Postural tremor	Weakness	Sensory loss (LE)	Plantar response	DTRs of LE	Other neurologic features
CHD-5	Learning difficulties, mood disorder	77	No	No	NA	No	No	Normal	Absent	Migraine
CHD-6	Learning difficulties (mild), mood disorder	NA	Limb dysmetria	Parkinsonism ^a	No	Diffuse LE and UE	Distal vibratory loss	Extensor	Absent	Wheelchair bound
CHD-17	Learning disability, irritability, ADHD	87	No	No	No	No	Distal vibratory loss	Normal	Decreased	Spasticity as infant, febrile seizure
CHD-18	Learning disability, ADHD	95	Limb dysmetria	Hand cramps	Mild	Mild distal LE	No	Extensor	Absent	
CHD-19	Learning disability, ADHD	81	Limb dysmetria	Parkinsonism	Mild	Mild distal LE	No	Normal	Absent	
CHD-20	Learning disability	67	Limb dysmetria, gait ataxia	NA	NA	Diffuse LE and UE	Distal vibratory loss	Extensor	Absent	
CHD-23	Learning difficulties	85	Limb dysmetria, gait ataxia	Parkinsonism ^{a,b,c}	No	Diffuse LE and UE	Distal vibratory loss	Extensor	Absent	Vivid/active dreaming, uses wheelchair, AFOs
CHD-24	Learning difficulties, ADD	64	No	No	No	Bilateral foot drop	No	Normal	Absent	AFOs
CHD-26	Learning disability	83	Limb dysmetria	Parkinsonism, axial dystonia ^a	Mild	Mild bilateral LE	No	Normal	Absent	Vivid/active dreaming

Abbreviations: ADD = attention deficit disorder; ADHD = attention deficit/hyperactivity disorder; AFO = ankle foot orthosis; DTR = deep tendon reflex; FSIQ = full-scale intelligence quotient; LE = lower extremity; NA = not assessed; UE = upper extremity.

^aL-Dopa responsive.

^b"On-off" fluctuations.

^cL-Dopa-induced dyskinesia.

clustering in the perinuclear cytoplasm, and fail to distribute normally into the periphery of cells.

The bloated lysosome-like organelles of CHD cells account for many of the manifestations of the disease.²⁰ Enlarged melanosomes in melanocytes move poorly along dendritic processes, and skin melanosomes cannot transfer melanin to surrounding keratinocytes,^{4,8,20} resulting in hypopigmentation. The trafficking defect in CHD megakaryocytes results in absent or deficient platelet dense bodies, impairing the secondary aggregation response and resulting in bruising and mucous membrane bleeding.²⁰ In dendritic cells, giant lysosomes cannot migrate to and ingest pathogens, accounting for susceptibility to infections. The cause of the accelerated phase in CHD could be related to defective trafficking of perforin and, consequently, impaired apoptosis induced by lymphocytic cells.

The basis for nervous system involvement in CHD remains enigmatic. We do not know if progressive neurodegeneration emerges from the accumulation of undigested substrate in giant lysosomes, from impaired LRO trafficking along neuritic processes of Purkinje cells, corticospinal neurons, anterior horn cells, and other neuronal populations, or from dysfunctional vesicle incorporation into membranes.

In an early phase of CHD, features of developmental delay, learning difficulties, or attention deficit/hyperactivity disorder are nearly universal and

reflect a developmental disturbance, supported by our finding of structural variations in the configuration of the posterior fossa. This nonspecific abnormality likely reflects variable degrees of cerebellar hypoplasia, especially in the midline cerebellum. We found similar MRI findings in all patients with CHD (including infants) prior to any hematologic complications compared to patients with classic CHD who had undergone BMT (unpublished observation).

A second phase of the illness appears around late adolescence, and manifests as a gradual and progressive neurologic decline. Progressive atrophic MRI changes in the cerebrum and cerebellum correlate with clinical worsening and increased disability. Generally, mild and nonspecific incoordination appears at school age, while well-defined midline cerebellar dysfunction and limb dysmetria, common features in mild CHD, occur in early adulthood. *LYST* variants in humans and in a missense *Lyst*^{L3618R} murine model of CHD²¹ appear to target Purkinje cells. Young adults with CHD have diminished or absent deep tendon reflexes resulting from a length-dependent, predominantly axonal polyneuropathy, commonly presenting as foot drop. Once present, progression occurs rapidly. Long tract signs, including spasticity and extensor plantar responses, are common but often obscured by weakness and atrophy associated with the coexisting peripheral

Figure 3 Brain MRIs of patients with atypical Chediak-Higashi disease (CHD)

Midline MRI sagittal images for 6 patients with atypical CHD obtained at the time of their initial evaluation. (A–F) Patients CHD-6, 19, 24, 17, 23, and 20. The tentorial angle (in degrees) and lines converging on the tentorial angle are represented for each image. (G) Similarly processed image in one representative age-matched control. (H, I) Coronal MRI views at the level of the cerebellar hemispheres for mild (case CHD-23) and advanced (case CHD-20) neurologic impairment demonstrate cerebral and cerebellar atrophy in the more severely affected patient.

neuropathy. In late stages, individuals lose the ability to ambulate and perform activities of daily living. We speculate that *LYST* dysfunction uncovers vulnerabilities in membrane repair, bioenergetics, vesicular trafficking, and cytoskeleton maintenance. In vitro studies demonstrate failure of cultured melanocytes from patients with CHD to properly traffic and release their pigment cargo to the extracellular space.⁸ Both human CHD cells and those of the *beige* murine CHD model have defective lysosomal exocytosis and plasma membrane repair²²; these deficiencies likely contribute to neuronal degeneration and neurologic dysfunction.

CHD may present as parkinsonism. Other patients may experience limb dystonia. Four of our patients, and others in the literature,^{23–27} have levodopa-responsive parkinsonism not unlike Parkinson disease (PD).²⁸ Two of our patients undergoing L-dopa replacement therapy for longer than 3 years

experienced “on-off” fluctuation and L-dopa-induced dyskinesia consistent with a progressive presynaptic dopaminergic deficit. Two patients experienced RBD, a condition long regarded as an early feature of synucleinopathies, suggesting that *LYST* dysfunction may also influence the proteosomal degradation system and autophagy. LRO dysfunction occurs in several monogenic forms of PD,²⁹ most notably in Gaucher disease. Reduced vesicle fission in CHD is likely to adversely affect other neuronal processes such as vesicular packaging of dopamine, which might contribute to neurodegeneration.^{30,31}

While classic hematologic and pigmentary features of CHD are recapitulated in the *beige* mouse model due to deletions within *Lyst*,³² the neurologic characteristics of mild CHD are best exemplified in another CHD murine model with a homozygous *Lyst*^{J3618R} missense variant. These animals, with a silvery gray coat and prolonged bleeding, have no evidence of

ocular albinism, blood cell dysmorphology, susceptibility to infection, or development of HLH.²¹ Instead, they have an age-dependent neurologic phenotype consisting of late-onset cerebellar dysfunction and motor coordination deficits. Their brains revealed no abnormalities in young mice, but by 5 months, giant inclusions appeared, primarily in the cerebellum. The Purkinje cells are laden with giant vesicular inclusions at the base of their dendritic arborization. With advancing age, these changes evolved into substantial Purkinje cell degeneration.²¹

For decades, the neurologic findings of CHD were masked by the disease's early, fatal infections and HLH. Now, bone marrow transplantation and mildly affected individuals are making the neurologic aspects of CHD apparent. Ascertainment remains challenging for patients with mild disease, largely because of the vague, varied, and nonspecific nature of their neurologic phenotypes. Neurologists should suspect CHD when they encounter individuals with subtle neurologic signs and any combination of skin or ocular pigment dilution, bleeding tendency, or unusual infectious history. Given their early learning disabilities, cognitive issues, and soft neurologic findings, many young patients with mild CHD may carry static diagnoses such as developmental delay or cerebral palsy. However, the neurologic involvement of CHD progresses inexorably. For some patients with CHD with parkinsonism, standard dopaminergic therapy produces substantial, life-changing benefits, at least in the short term. For others, proper adaptive equipment, vocational counseling, and physical and occupation rehabilitation can improve quality of life. Finally, our patient CHD-20 is a powerful reminder that the accelerated phase can occur at any age, and patients should be closely monitored for any suggestion of HLH.

AUTHOR CONTRIBUTIONS

W.J.I., W.W., W.A.G., and C.T. designed the study and drafted the first draft of the manuscript. All authors collected and interpreted data. All authors participated in manuscript revision.

ACKNOWLEDGMENT

The authors thank Roxanne Fischer and Isa Bernardini for clinical and laboratory work and the patients and families who participated in this research.

STUDY FUNDING

Supported by the Intramural Research Programs of the National Human Genome Research Institute, the National Institute of Neurological Disorders and Stroke, and the Hatfield Clinical Center, NIH, Bethesda, MD.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received September 15, 2015. Accepted in final form December 17, 2015.

REFERENCES

1. Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. *Nat Genet* 1996;14:307–311.
2. Blume RS, Wolff SM. The Chediak-Higashi syndrome: studies in four patients and a review of the literature. *Medicine* 1972;51:247–280.
3. Jessen B, Maul-Pavicic A, Ufheil H, et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. *Blood* 2011;118:4620–4629.
4. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. *Mol Genet Metab* 1999;68:283–303.
5. Tardieu M, Lacroix C, Neven B, et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. *Blood* 2005;106:40–42.
6. Introne WJ, Westbrook W, Golas GA, Adams D. Chediak-Higashi syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. *GeneReviews*. Seattle: University of Washington; 2009:1993–2015.
7. Karim MA, Suzuki K, Fukai K, et al. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. *Am J Med Genet* 2002;108:16–22.
8. Westbrook W, Adams D, Huizing M, et al. Cellular defects in Chediak-Higashi syndrome correlate with the molecular genotype and clinical phenotype. *J Invest Dermatol* 2007;127:2674–2677.
9. Liveson JA. *Laboratory Reference for Clinical Neurophysiology*. New York: Oxford University Press; 1992.
10. Markunas CA, Enterline DS, Dunlap K, et al. Genetic evaluation and application of posterior cranial fossa traits as endophenotypes for Chiari type I malformation. *Ann Hum Genet* 2014;78:1–12.
11. Manoli I, Golas G, Westbrook W, et al. Chediak-Higashi syndrome with early developmental delay resulting from paternal heterodisomy of chromosome 1. *Am J Med Genet A* 2010;152A:1474–1483.
12. Zarzour W, Kleta R, Frangoul H, et al. Two novel CHS1 (LYST) mutations: clinical correlations in an infant with Chediak-Higashi syndrome. *Mol Genet Metab* 2005;85:125–132.
13. Burkhardt JK, Wiebel FA, Hester S, Argon Y. The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes. *J Exp Med* 1993;178:1845–1856.
14. Wechsler D. *Wechsler Abbreviated Scale of Intelligence*. San Antonio: Psychological Corporation; 1999.
15. Wechsler D. *Wechsler Adult Intelligence Scale*, 3rd ed. San Antonio: Psychological Corporation; 1997.
16. Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. *Curr Opin Hematol* 2008;15:22–29.
17. Sanchez-Guiu I, Anton AI, Garcia-Barbera N, et al. Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. *Eur J Hematol* 2014;92:49–58.
18. Cullinane AR, Schaffer AA, Huizing M. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. *Traffic* 2013;14:749–766.
19. Durchfort N, Verhoef S, Vaughn MB, et al. The enlarged lysosomes in beige j cells result from decreased lysosome

- fission and not increased lysosome fusion. *Traffic* 2012;13:108–119.
20. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. *Annu Rev Genomics Hum Genet* 2008;9:359–386.
21. Rudelius M, Osanger A, Kohlmann S, et al. A missense mutation in the WD40 domain of murine Lyst is linked to severe progressive Purkinje cell degeneration. *Acta Neuropathol* 2006;112:267–276.
22. Huynh C, Roth D, Ward DM, Kaplan J, Andrews NW. Defective lysosomal exocytosis and plasma membrane repair in Chediak-Higashi/beige cells. *Proc Natl Acad Sci USA* 2004;101:16795–16800.
23. Jacobi C, Koerner C, Fruehauf S, Rottenburger C, Storch-Hagenlocher B, Grau AJ. Presynaptic dopaminergic pathology in Chediak-Higashi syndrome with parkinsonian syndrome. *Neurology* 2005;64:1814–1815.
24. Silveira-Moriyama L, Moriyama TS, Gabbi TV, Ranvaud R, Barbosa ER. Chediak-Higashi syndrome with parkinsonism. *Mov Disord* 2004;19:472–475.
25. Hauser RA, Friedlander J, Baker MJ, Thomas J, Zuckerman KS. Adult Chediak-Higashi parkinsonian syndrome with dystonia. *Mov Disord* 2000;15:705–708.
26. Uyama E, Hirano T, Ito K, et al. Adult Chediak-Higashi syndrome presenting as parkinsonism and dementia. *Acta Neurol Scand* 1994;89:175–183.
27. Pettit RE, Berdal KG. Chediak-Higashi syndrome: neurologic appearance. *Arch Neurol* 1984;41:1001–1002.
28. Bhambhani V, Introne WJ, Lungu C, Cullinane A, Toro C. Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism. *Mov Disord* 2013;28:127–129.
29. Hardy J. Genetic analysis of pathways to Parkinson disease. *Neuron* 2010;68:201–206.
30. Guillot TS, Miller GW. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. *Mol Neurobiol* 2009;39:149–170.
31. Anderson DG, Mariappan SV, Buettner GR, Doorn JA. Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. *J Biol Chem* 2011;286:26978–26986.
32. Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. *Nature* 1996;382:262–265.